Breaking News

Gilead to Acquire Remaining Rights to GS-1811 from Jounce Therapeutics

GS-1811 is a potentially first-in-class immunotherapy designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments due under the license agreement from August 2020.  As part of the transaction, certain obligations of the parties related to GS-1811, an anti-CCR8 antibody, in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights to GS-1811 and Jo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters